

**Expert Workshop:**  
**Facilitating Antibacterial Drug Development**  
The Brookings Institution • Washington, DC  
Wednesday, May 9, 2012

**Agenda**

- 8:30 a.m. Welcome and Overview**  
Mark McClellan, Engelberg Center for Health Care Reform at Brookings
- 8:45 a.m. Remarks from FDA: Current and Future Status of Antibacterial Drug Development**  
Janet Woodcock, U.S. Food and Drug Administration
- 9:00 a.m. Existing Paradigms for Antibacterial Drug Development**  
Mark McClellan – *Moderator*  
Brad Spellberg, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center  
George Talbot, Talbot Advisors LLC  
Thomas Fleming, University of Washington School of Public Health  
John Powers, National Institutes of Health and George Washington University School of Medicine
- 9:50 a.m. Pharmacokinetics and Pharmacodynamics (PK/PD) in Antibacterial Drug Development and Bayesian Methods in Clinical Research**  
Rob Califf, Duke Translational Medicine Institute, Duke University Medical Center – *Moderator*  
George Drusano, University of Florida College of Medicine  
Scott Emerson, University of Washington
- 10:40 a.m. Break**
- 10:50 a.m. Novel Approaches to Further Antibacterial Drug Development: New Approaches to the Clinical Development Program**  
Rob Califf – *Moderator*  
John Rex, AstraZeneca Pharmaceuticals and University of Texas Medical School at Houston  
Daniel Benjamin, Duke Clinical Research Institute, Duke University School of Medicine  
Richard Platt, Harvard Pilgrim Health Care and Harvard Medical School  
Edward Cox, U.S. Food and Drug Administration
- 12:00 p.m. Working Lunch**
- 12:50 p.m. Outlining the Path Forward**  
Mark McClellan – *Moderator*  
Helen Boucher, Tufts Medical Center and Tufts University School of Medicine  
Barry Eisenstein, Cubist Pharmaceuticals and Harvard Medical School  
Louis Rice, Warren Alpert Medical School of Brown University, Rhode Island Hospital and The Miriam Hospital  
Rachel Sherman, U.S. Food and Drug Administration
- 2:20 p.m. Recap and Closing Remarks**  
Mark McClellan
- 2:30 p.m. Adjournment**